Joseph L Turner
CIK 1266129 · last filed 2022-06-03
Joseph L Turner is a corporate insider who has filed 35 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for ARQT, was dated Jun 3, 2022. Across all open-market trades the lifetime net is +$20.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $864.6K across reported positions. 3 SEC filings were submitted jointly with QLT INC/BC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CORT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARQT | Director | 4,312 | $25.40 | $109.5K | $0 | 3 | 2022-06-03 |
| VRDN | Director | — | $29.89 | — | $0 | 1 | 2021-02-08 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 4 | 2020-05-22 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | 0 | — | — | $0 | 5 | 2015-10-02 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Director | — | — | — | $0 | 4 | 2015-06-25 |
| CORT | Director | 10,000 | $75.50 | $755.0K | $20.1K | 8 | 2015-06-23 |
| SOPHIRIS BIO INC. (SPHS) Delisted | Director | — | — | — | $0 | 2 | 2015-05-28 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 0 | — | — | $0 | 1 | 2012-09-05 |
| QLTI | Director | — | $28.44 | — | $0 | 2 | 2011-05-27 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | — | — | — | $0 | 4 | 2008-08-21 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-03 | ARQT | Grant (A) | +4,312 | $0 | EDGAR |
| 2021-06-11 | ARQT | Grant (A) | — | $0 | EDGAR |
| 2021-02-08 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2020-05-22 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-03 | ARQT | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-28 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-30 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-21 | — | Mixed | −1,050 | $0 | |
| 2015-10-02 | KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Disp (D) | −1,872 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.